PRECEDE Study Aims to Increase Early Detection in Pancreatic Cancer SAN DIEGO, CA / ACCESSWIRE / November 1, 2024 / Pancreatic cancer has the lowest five-year survival rate of all major cancers at a shockingly low 13%, and it is the third leading cause of cancer mortality in the United States. The need for early detection of pancreatic cancer through enhanced screening tools is vital, as pancreatic cancer is often detected at the latest stages when treatment is no longer effective. https://precedestudy.
org PRECEDE Consortium PRECEDE Consortium A dedicated team of researchers, physicians and scientists are coming together in San Diego on November 7 and 8 for the annual meeting of the global Pancreatic Cancer Early Detection (PRECEDE) Study , an interconnected set of 51 pancreatic centers worldwide conducting unprecedented research for the early detection of pancreatic cancer in individuals with increased risk for the disease. Founded in 2020, the international PRECEDE Study ( https://precedestudy.org ) is open to individuals with a family history of pancreatic cancer and/or those who carry genetic variants linked to development of the cancer.
The PRECEDE Study is now headquartered out of Moores Cancer Center at UC San Diego Health, and the international group will gather at the Estancia La Jolla for two days of informational panels, partner updates, collaboration and sharing of information. Through the PRECEDE collaborative network throughout North America, Europe, the Middle .